NZ511984A - Controlled release formulation comprising GnRH-II - Google Patents

Controlled release formulation comprising GnRH-II

Info

Publication number
NZ511984A
NZ511984A NZ511984A NZ51198499A NZ511984A NZ 511984 A NZ511984 A NZ 511984A NZ 511984 A NZ511984 A NZ 511984A NZ 51198499 A NZ51198499 A NZ 51198499A NZ 511984 A NZ511984 A NZ 511984A
Authority
NZ
New Zealand
Prior art keywords
controlled release
xaa1
xaa3
xaa2
tyr
Prior art date
Application number
NZ511984A
Inventor
Steve Qi
Karen Akinsanya
Amanda Hayward
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of NZ511984A publication Critical patent/NZ511984A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

A pharmaceutical formulation for the controlled release of a therapeutic peptide or a salt thereof, which peptide has the sequence pyroGlu-His-Trp-Ser-Xaa1-Gly-Xaa2-Xaa3-Pro-Gly-NH2 wherein Xaa1 is His or Tyr, ```Xaa2 is Trp or Leu, and ```Xaa3 is Tyr or Arg, provided that when Xaa1 is Tyr and Xaa2 is Leu, then Xaa3 is not Arg, and which formulation further comprises a pharmaceutically acceptable biodegradable polymer preferably a co-polymer of glycolic and lactic acids. The formulation can be used for treating bone and prostate disorders.
NZ511984A 1998-12-03 1999-12-02 Controlled release formulation comprising GnRH-II NZ511984A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9826662A GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation
PCT/GB1999/004045 WO2000032218A1 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii

Publications (1)

Publication Number Publication Date
NZ511984A true NZ511984A (en) 2002-11-26

Family

ID=10843631

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ511984A NZ511984A (en) 1998-12-03 1999-12-02 Controlled release formulation comprising GnRH-II

Country Status (22)

Country Link
EP (1) EP1140133A1 (en)
JP (1) JP2002531411A (en)
KR (1) KR20010089538A (en)
CN (1) CN1332635A (en)
AU (1) AU770676B2 (en)
BR (1) BR9915943A (en)
CA (1) CA2353798A1 (en)
CZ (1) CZ20011893A3 (en)
EE (1) EE200100293A (en)
GB (1) GB2344287A (en)
HR (1) HRP20010421A2 (en)
HU (1) HUP0104943A3 (en)
IL (1) IL143496A0 (en)
MX (1) MXPA01005543A (en)
NO (1) NO20012636L (en)
NZ (1) NZ511984A (en)
PL (1) PL348575A1 (en)
RU (1) RU2233170C2 (en)
SK (1) SK7552001A3 (en)
TR (1) TR200102273T2 (en)
WO (1) WO2000032218A1 (en)
ZA (1) ZA200104530B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334258B2 (en) 2005-07-26 2012-12-18 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts (Universitätsmedizin) Method for induction and enhancement of apoptosis in tumor cells
GB0616111D0 (en) 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2411038B1 (en) 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
WO2011056572A1 (en) 2009-10-27 2011-05-12 The Board Of Trustees Of The University Of Illinois Methods of diagnosing diastolic dysfunction
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
DK2547359T3 (en) 2010-03-15 2016-06-06 The Board Of Trustees Of The Univ Of Illionis Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
US20120004182A1 (en) 2010-07-02 2012-01-05 Carsten Gruendker Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
US20140221283A1 (en) 2011-06-22 2014-08-07 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2013055791A1 (en) 2011-10-10 2013-04-18 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
ES2672880T3 (en) 2011-11-17 2018-06-18 Indiana University Research And Technology Corporation Glucagon superfamily peptides showing glucocorticoid receptor activity
EP2793932B1 (en) 2011-12-20 2018-10-03 Indiana University Research and Technology Corporation Ctp-based insulin analogs for treatment of diabetes
KR20150023729A (en) 2012-06-14 2015-03-05 암브룩스, 인코포레이티드 Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
PE20150863A1 (en) 2012-06-21 2015-06-11 Univ Indiana Res & Tech Corp GLUCAGON ANALOGS DISPLAYING GIP RECEPTOR ACTIVITY
CN104583232B (en) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 Show the glucagon analogs of GIP receptor actives
AU2013323669B2 (en) 2012-09-26 2018-03-01 Indiana University Research And Technology Corporation Insulin analog dimers
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
CN107683289B (en) 2015-01-26 2021-08-06 芝加哥大学 IL13R alpha 2 binding agents and their use in cancer treatment
EP3250611B1 (en) 2015-01-26 2021-04-21 The University of Chicago Car t-cells recognizing cancer-specific il 13r-alpha2
CN104789524A (en) * 2015-04-30 2015-07-22 四川大学 Osteoporotic rat primary osteoblasts isolated culture method and application thereof
WO2017024111A1 (en) 2015-08-04 2017-02-09 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
EP3571213A1 (en) * 2017-01-20 2019-11-27 Immune System Regulation Holding AB Novel compounds (immunorhelins)
MX2020000190A (en) 2017-06-30 2020-07-22 Amgen Inc Methods of treating heart failure with cardiac sarcomere activators.
PT3661954T (en) 2017-08-03 2022-04-14 Amgen Inc Interleukin-21 muteins and methods of treatment
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
CN111565744A (en) 2017-09-18 2020-08-21 加利福尼亚大学董事会 Claudin 6 antibodies and methods of treating cancer
SG11202005605SA (en) 2018-01-12 2020-07-29 Amgen Inc Anti-pd-1 antibodies and methods of treatment
WO2020055913A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of reducing- c-reactive protein and/or treating cardiovascular disease
SG11202109986TA (en) 2019-03-20 2021-10-28 Univ California Claudin-6 antibodies and drug conjugates
JP7066913B2 (en) * 2019-03-26 2022-05-13 ノベルファーマ株式会社 Persistent fatty acid-bound GnRH derivative and pharmaceutical composition containing it
US20220160872A1 (en) 2019-04-09 2022-05-26 The Board Of Trustees Of The University Of Illinois Drug Adsorbed Highly Porous Activated Carbon for Enhanced Drug Delivery
US20230190725A1 (en) 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
BR112021021663A2 (en) 2019-04-30 2022-05-17 Inst De Medicina Molecular Joao Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors
JP2022538829A (en) 2019-06-24 2022-09-06 アムジェン インコーポレイテッド Inhibition of SIRPγ for cancer therapy
JP2022546700A (en) 2019-08-30 2022-11-07 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Copper-ATSM for the treatment of neurodegenerative disorders associated with mitochondrial dysfunction
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
CA3208974A1 (en) 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (en) * 1983-09-23 1987-07-15 Debiopharm Sa PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES.
DE3414595A1 (en) * 1984-04-18 1985-10-31 Hoechst Ag, 6230 Frankfurt USE OF GONADOLIBERIN AND GONADOLIBERINAGONISTS FOR TREATING CLIMATE COMPLAINTS
US4540513A (en) * 1984-09-25 1985-09-10 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Decapeptide having gonadotropin releasing activity
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
IT1243390B (en) * 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
WO1997047743A1 (en) * 1996-06-13 1997-12-18 Zymogenetics, Inc. Human type ii gonadotropin-releasing hormone receptor

Also Published As

Publication number Publication date
MXPA01005543A (en) 2003-07-14
PL348575A1 (en) 2002-06-03
TR200102273T2 (en) 2001-12-21
NO20012636L (en) 2001-07-12
HRP20010421A2 (en) 2002-06-30
BR9915943A (en) 2001-08-21
GB2344287A (en) 2000-06-07
NO20012636D0 (en) 2001-05-29
RU2233170C2 (en) 2004-07-27
AU770676B2 (en) 2004-02-26
SK7552001A3 (en) 2002-02-05
AU1573200A (en) 2000-06-19
HUP0104943A2 (en) 2002-06-29
IL143496A0 (en) 2002-04-21
EP1140133A1 (en) 2001-10-10
HUP0104943A3 (en) 2002-08-28
JP2002531411A (en) 2002-09-24
WO2000032218A1 (en) 2000-06-08
ZA200104530B (en) 2002-06-04
KR20010089538A (en) 2001-10-06
EE200100293A (en) 2002-08-15
GB9826662D0 (en) 1999-01-27
CN1332635A (en) 2002-01-23
CZ20011893A3 (en) 2002-05-15
CA2353798A1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
NZ511984A (en) Controlled release formulation comprising GnRH-II
EP2286799A3 (en) Microspheres for active embolization
CA2235919A1 (en) Non-polymeric sustained release delivery system
EP0737703A3 (en) Hydrogel-forming , self-solvating absorbable polyester copolymers, and methods for use therefor
MX9603858A (en) Block and graft copolymers and methods relating thereto.
CA2195119A1 (en) Formulations and methods for providing prolonged local anesthesia
EP0952171A3 (en) Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
AU655187B2 (en) Continuous release pharmaceutical compositions
DE69925936D1 (en) DEVICE FOR THE LOCAL ADMINISTRATION OF A MEDICINE IN A BODY HEIGHT
EP1125577A3 (en) Liquid drug delivery compositions
ATE208612T1 (en) BIOLOGICALLY ERODABLE DEVICE FOR ADMINISTRATION OF ACTIVE INGREDIENTS
PL312219A1 (en) Application of nona- and decapeptides in obtaining a therapeutic agent for fighting against aids
RU2001118040A (en) CONTROLED RELEASE COMPOSITION INCLUDING GNRH-II
WO2003105703A3 (en) Multi-point tension distribution system device and method of tissue approximation using that device to improve wound healing
HK1153377A1 (en) A buprenorphine transdermal patch for use in the treatment of pain for a dosing interval of at least 7 days
AU1999995A (en) An adjunctive polymer system for use with medical device
HK1022275A1 (en) Sustained peptide-release formulation.
AU2603400A (en) Formulations for treating disease and methods of using same
NL300330I1 (en) Preparation for delivering peptides
WO2001072280A3 (en) Microspheres for gene therapy
PT885014E (en) PHARMACEUTICAL COMPOSITIONS CONTAINING POLYMERS ORTO ESTER TAMPONADOS
HUP0003840A2 (en) Controlled released medical formulation
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
NZ509031A (en) A disk formed from a filmogenic polymer carrying a therapeutic agent selected from a stabiliser, a solubiliser, an enhancer and a plasticiser
WO2003008005A3 (en) Catheter and implants for the delivery of therapeutic agents to tissues

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)